Medifast (NYSE:MED) Raised to “Hold” at Wall Street Zen

Medifast (NYSE:MED) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

MED has been the topic of several other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. Stephens lowered their price objective on Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, February 19th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $12.00.

Medifast Price Performance

Shares of Medifast stock opened at $10.01 on Friday. The company has a 50-day moving average of $10.93 and a 200 day moving average of $11.80. The firm has a market cap of $110.00 million, a price-to-earnings ratio of -5.85 and a beta of 0.52. Medifast has a 1 year low of $9.22 and a 1 year high of $15.46.

Medifast (NYSE:MED) last posted its quarterly earnings data on Tuesday, February 17th. The specialty retailer reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.21. The business had revenue of $75.10 million for the quarter, compared to analyst estimates of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. On average, equities analysts anticipate that Medifast will post 0.51 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its position in shares of Medifast by 261.8% during the second quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer’s stock valued at $28,000 after acquiring an additional 1,448 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the last quarter. Quantbot Technologies LP bought a new position in Medifast in the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management bought a new position in Medifast in the 4th quarter valued at approximately $47,000. Finally, State of Wyoming purchased a new stake in Medifast during the 4th quarter valued at $59,000. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.